Tag:

M&A

Latest Headlines

Latest Headlines

AstraZeneca CEO says Pfizer won't come back. Oh, and that $45B goal? It's a stretch

In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.

Roche continues diagnostics winning streak with Bina Tech acquisition

Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.

Poland's KCR expands its Euro reach with latest deal

Contract researcher KCR is dialing up its presence in Ukraine, buying out a competitor's whole clinical portfolio and doubling down on a country it believes is ripe for R&D growth.

Deal-happy Actavis eyes Spain's Almirall for European growth: Bloomberg

Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.

Established product sales lacking in pharma's whopper M&A year

2014 may have been a banner year in pharma M&A, but for companies looking to sell off their portfolios of aging meds, it wasn't quite big enough.

Salix investors pushing for sale once supply issues wrap

Salix is working quickly to get some inventory issues under control after bidding farewell to its CFO and launching an audit committee review. But as soon as it does, some shareholders want the North Carolina drugmaker to put itself on the block.

Roche boosts its antibody arsenal with a $489M buyout

Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $488.8 million and get its hands on some proprietary technology.

Flush-with-cash Shire revisits deal for NPS Pharma

Armed with a $1.64 billion breakup fee from former merger partner AbbVie and a brand-new $2.1 billion revolving loan facility, Shire looks ready to strike a deal. Rumor says it's revisiting some of its old targets, including New Jersey's NPS Pharmaceuticals.

Imaging specialist Varian to increase software focus with purchase of MeVis

Mobile medical apps are all the rage, but software is growing in importance in traditional medical devices too, as evidenced by Varian Medical Systems announcement that it will acquire Germany's MeVis Medical Solutions AG, a provider of software for cancer imaging.

UPDATED: Merck beefs up its cancer drug pipeline in $375M OncoEthix buyout

Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.